Skip to content
drillr.ai
Sign up

GILD

GILEAD SCIENCES, INC.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$153.07
−2.00%
Ask drillr

  • Oct 19, 2026, 12:00 UTC

    Gilead Sciences said it will present 28 research presentations, including two oral presentations, at Innoviva, Inc. 2026 on HIV treatment, prevention, and emerging antiviral programs.

    Source:

  • Oct 19, 2026, 10:41 UTC

    GILEAD SCIENCES, INC. reported that its pill succeeded in a mid-stage trial for bowel disease.

    Source:

  • Oct 19, 2026, 08:35 UTC

    GILEAD SCIENCES, INC. reported Phase 2 results showing its emvistegrast treatment produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis after a 200 mg daily dose for 12 weeks.

    Source:

  • Oct 15, 2026, 23:00 UTC

    GILEAD SCIENCES, INC. closed at $157.48, up 2.57% from the previous trading session.

    Source:

  • Oct 14, 2026, 22:45 UTC

    The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.

    Source:

  • Oct 14, 2026, 16:58 UTC

    Vir Biotechnology, Inc. and GILEAD SCIENCES, INC. announced a collaboration to create three T-cell engagers for treating solid tumors.

    Source:

  • Oct 14, 2026, 12:42 UTC

    Vir Biotechnology entered into a stock purchase agreement to issue 1,765,486 shares of common stock to Gilead Sciences for $14.16 per share, or $25 million in total.

  • Oct 7, 2026, 06:45 UTC

    COGNIZANT TECHNOLOGY SOLUTIONS CORP extended its partnership with GILEAD SCIENCES, INC. for five years to support selected technology programs, including DevOps and AI-enabled workflows.

    Source:

  • Oct 5, 2026, 11:00 UTC

    Nurix Therapeutics and Gilead Sciences agreed to extend the research term for an undisclosed oncology program within their ongoing strategic collaboration by an additional two years.

    Source:

  • Oct 2, 2026, 22:50 UTC

    Gilead Sciences (GILD) shares fell 1.87% to close at $144.74 on the most recent trading day.

    Source:

  • Oct 1, 2026, 12:35 UTC

    Vir Biotechnology, Inc. appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.

  • Sep 30, 2026, 23:00 UTC

    Gilead Sciences (GILD) shares declined 1.21% to close at $149.45 in the latest trading session.

    Source:

  • Sep 30, 2026, 22:00 UTC

    Gilead Sciences will supply its HIV prevention drug lenacapavir to 24 low- and middle-income countries through partnerships with the Global Fund and PEPFAR, as announced by CEO Daniel O'Day at the Clinton Global Initiative conference in New York.

    Source:

  • Sep 23, 2026, 12:17 UTC

    Justin Gunn was appointed President, Endocrinology at Corcept Therapeutics effective October 1, 2026.

  • Sep 16, 2026, 14:30 UTC

    Gilead Sciences committed to advancing a technology-transfer process in Brazil aimed at enabling future local production of lenacapavir.

    Source:

  • Sep 16, 2026, 14:30 UTC

    The Pan American Health Organization (PAHO) announced an agreement with Gilead Sciences to make lenacapavir available for HIV prevention in 14 Latin American and Caribbean countries through its Regional Revolving Funds.

    Source:

  • Sep 16, 2026, 12:32 UTC

    Gilead Sciences extended six royalty-free licensing agreements covering 120 countries.

    Source:

  • Sep 13, 2026, 01:45 UTC

    Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.

    Source:

  • Sep 8, 2026, 20:00 UTC

    Assembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.

    Source:

  • Sep 8, 2026, 17:00 UTC

    Gilead opened a state-of-the-art research center in Foster City, California, to advance the next generation of medicines.

    Source:

  • Aug 28, 2026, 18:02 UTC

    The FDA approved Priovant Therapeutics' Lisraya for dermatomyositis, Gilead Sciences' Bixlenvo for HIV, and an expanded cardiovascular indication for Eli Lilly's Mounjaro.

    Source:

  • Aug 24, 2026, 11:50 UTC

    Qinhao Pharmaceutical licensed global rights of its MAT2A inhibitor GH31 to Gilead Sciences, generating revenue and net profit in the first five months of 2026.

    Source:

  • Aug 22, 2026, 07:12 UTC

    Advisors Capital Management LLC acquired a new position in Gilead Sciences, Inc. by purchasing 31,697 shares worth approximately $4,005,000 during the quarter ended before August 22, 2026.

    Source:

  • Aug 20, 2026, 07:13 UTC

    Abacus FCF Advisors LLC purchased a new stake of 59,974 shares in Gilead Sciences, Inc. during the second quarter, valued at approximately $7,577,000.

    Source:

  • Aug 17, 2026, 08:53 UTC

    AMG National Trust Bank purchased 26,675 shares of Gilead Sciences, Inc., valued at approximately $3,370,000, during the undefined quarter, as disclosed in a recent SEC filing.

    Source:

  • Aug 15, 2026, 08:07 UTC

    Abundance Wealth Counselors increased its stake in Gilead Sciences, Inc. by 93.7% during the quarter, acquiring an additional 10,710 shares, according to its SEC filing.

    Source:
Page 1Next →